Sphingosine 1-phosphate Lyase Facilitates Cancer Progression Through Converting Sphingolipids to Glycerophospholipids

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2022 Sep 20

PMID 36125914

Authors

Baasanjav Uranbileg

Makoto Kurano

Kuniyuki Kano

Eri Sakai

Junichi Arita

Kiyoshi Hasegawa

Takeshi Nishikawa

Soichiro Ishihara

Hiroharu Yamashita

Yasuyuki Seto

Hitoshi Ikeda

Junken Aoki

Yutaka Yatomi

Affiliations

Soon will be listed here.

Abstract

Background: In addition to potent agonist properties for sphingosine 1-phosphate (S1P) receptors, intracellularly, S1P is an intermediate in metabolic conversion pathway from sphingolipids to glycerolysophospholipids (glyceroLPLs). We hypothesized that this S1P metabolism and its products might possess some novel roles in the pathogenesis of cancer, where S1P lyase (SPL) is a key enzyme.

Methods: The mRNA levels of sphingolipid-related and other cancer-related factors were measured in human hepatocellular carcinoma (HCC), colorectal cancer, and esophageal cancer patients' tumours and in their adjacent non-tumour tissues. Phospholipids (PL) and glyceroLPLs were measured by using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In-vitro experiments were performed in Colon 26 cell line with modulation of the SPL and GPR55 expressions. Xenograft model was used for determination of the cancer progression and for pharmacological influence.

Results: Besides high SPL levels in human HCC and colon cancer, SPL levels were specifically and positively linked with levels of glyceroLPLs, including lysophosphatidylinositol (LPI). Overexpression of SPL in Colon 26 cells resulted in elevated levels of LPI and lysophosphatidylglycerol (LPG), which are agonists of GPR55. SPL overexpression-enhanced cell proliferation was inhibited by GPR55 silencing. Conversely, inhibition of SPL led to the opposite outcome and reversed by adding LPI, LPG, and metabolites generated during S1P degradation, which is regulated by SPL. The xenograft model results suggested the contribution of SPL and glyceroLPLs to tumour progression depending on levels of SPL and GPR55. Moreover, the pharmacological inhibition of SPL prevented the progression of cancer. The underlying mechanisms for the SPL-mediated cancer progression are the activation of p38 and mitochondrial function through the LPI, LPG-GPR55 axis and the suppression of autophagy in a GPR55-independent manner.

Conclusion: A new metabolic pathway has been proposed here in HCC and colon cancer, SPL converts S1P to glyceroLPLs, mainly to LPI and LPG, and facilitates cancer development.

Citing Articles

Mechanism research on inhibition of gastric cancer by the extract of based on network pharmacology and cellular metabolomics.

Feng F, Hu P, Chen J, Peng L, Wang L, Tao X Open Med (Wars). 2025; 20(1):20241131.

PMID: 39989612 PMC: 11843166. DOI: 10.1515/med-2024-1131.

Protective Role of Sphingosine-1-Phosphate During Radiation-Induced Testicular Injury.

Wang D, Xu R, Wang Z Antioxidants (Basel). 2024; 13(11).

PMID: 39594464 PMC: 11591009. DOI: 10.3390/antiox13111322.

Factors influencing survival in sphingosine phosphate lyase insufficiency syndrome: a retrospective cross-sectional natural history study of 76 patients.

Keller N, Midgley J, Khalid E, Lesmana H, Mathew G, Mincham C Orphanet J Rare Dis. 2024; 19(1):355.

PMID: 39334450 PMC: 11429486. DOI: 10.1186/s13023-024-03311-w.

Identification of the Metabolic Signature of Aging Retina.

Mu W, Han X, Tong M, Ben S, Yao M, Zhao Y Transl Vis Sci Technol. 2024; 13(8):8.

PMID: 39102240 PMC: 11309042. DOI: 10.1167/tvst.13.8.8.

Sphingosine kinase 2 and p62 regulation are determinants of sexual dimorphism in hepatocellular carcinoma.

Green C, Brown R, Uranbileg B, Weigel C, Saha S, Kurano M Mol Metab. 2024; 86:101971.

PMID: 38925249 PMC: 11261290. DOI: 10.1016/j.molmet.2024.101971.

References

Olivera A, Spiegel S . Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature. 1993; 365(6446):557-60. DOI: 10.1038/365557a0. View

Kihara A, Mitsutake S, Mizutani Y, Igarashi Y . Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate. Prog Lipid Res. 2007; 46(2):126-44. DOI: 10.1016/j.plipres.2007.03.001. View

Bandhuvula P, Honbo N, Wang G, Jin Z, Fyrst H, Zhang M . S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol Heart Circ Physiol. 2011; 300(5):H1753-61. PMC: 3094087. DOI: 10.1152/ajpheart.00946.2010. View

Makide K, Kitamura H, Sato Y, Okutani M, Aoki J . Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. Prostaglandins Other Lipid Mediat. 2009; 89(3-4):135-9. DOI: 10.1016/j.prostaglandins.2009.04.009. View

Nojiri K, Fudetani S, Arai A, Kitamura T, Sassa T, Kihara A . Impaired Skin Barrier Function Due to Reduced ω--Acylceramide Levels in a Mouse Model of Sjögren-Larsson Syndrome. Mol Cell Biol. 2021; 41(10):e0035221. PMC: 8462457. DOI: 10.1128/MCB.00352-21. View

Sukocheva O . Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming. Int J Mol Sci. 2018; 19(2). PMC: 5855642. DOI: 10.3390/ijms19020420. View

Sooro M, Zhang N, Zhang P . Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy. Int J Cancer. 2018; 143(9):2116-2125. DOI: 10.1002/ijc.31398. View

Bernardini M, Lee C, Beheshti B, Prasad M, Albert M, Marrano P . High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia. 2005; 7(6):603-13. PMC: 1501280. DOI: 10.1593/neo.04760. View

Cuvillier O, Pirianov G, Kleuser B, Vanek P, Coso O, Gutkind S . Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996; 381(6585):800-3. DOI: 10.1038/381800a0. View

10.

Nakahara K, Ohkuni A, Kitamura T, Abe K, Naganuma T, Ohno Y . The Sjögren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of the sphingosine 1-phosphate degradation pathway. Mol Cell. 2012; 46(4):461-71. DOI: 10.1016/j.molcel.2012.04.033. View

11.

Igarashi Y . Functional roles of sphingosine, sphingosine 1-phosphate, and methylsphingosines: in regard to membrane sphingolipid signaling pathways. J Biochem. 1998; 122(6):1080-7. DOI: 10.1093/oxfordjournals.jbchem.a021865. View

12.

Cartier A, Hla T . Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science. 2019; 366(6463). PMC: 7661103. DOI: 10.1126/science.aar5551. View

13.

Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E . Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell. 2009; 16(2):103-14. PMC: 2851205. DOI: 10.1016/j.ccr.2009.07.004. View

14.

Degagne E, Pandurangan A, Bandhuvula P, Kumar A, Eltanawy A, Zhang M . Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest. 2014; 124(12):5368-84. PMC: 4348973. DOI: 10.1172/JCI74188. View

15.

Zhang H, Desai N, Olivera A, Seki T, Brooker G, Spiegel S . Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol. 1991; 114(1):155-67. PMC: 2289065. DOI: 10.1083/jcb.114.1.155. View

16.

Wu M, Zhang P . EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Lett. 2019; 469:207-216. DOI: 10.1016/j.canlet.2019.10.030. View

17.

Kurano M, Tsukamoto K, Shimizu T, Kassai H, Nakao K, Aiba A . Protection Against Insulin Resistance by Apolipoprotein M/Sphingosine-1-Phosphate. Diabetes. 2020; 69(5):867-881. DOI: 10.2337/db19-0811. View

18.

Rabinowitz J, White E . Autophagy and metabolism. Science. 2010; 330(6009):1344-8. PMC: 3010857. DOI: 10.1126/science.1193497. View

19.

Sukocheva O, Furuya H, Ng M, Friedemann M, Menschikowski M, Tarasov V . Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther. 2019; 207:107464. DOI: 10.1016/j.pharmthera.2019.107464. View

20.

Apel A, Herr I, Schwarz H, Rodemann H, Mayer A . Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 2008; 68(5):1485-94. DOI: 10.1158/0008-5472.CAN-07-0562. View